Analysis Date: 2026-02-24T14:24:38.454992 Trading Period: 2025-12-25 to 2026-01-08
Company: SELLAS Life Sciences Group, Inc. Sector: Healthcare | Industry: Biotechnology Current Price: $4.50 Market Cap: $766,269,120 Beta: 2.25 Avg Volume: 8,348,775 Website: https://www.sellaslifesciences.com
Description: SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...
Action: STRONG AVOID Confidence: 20.0/100 Position Size: 0.0% of portfolio
Rationale: Unfavorable conditions (composite: 54.8/100, risk: EXTREME, red flags: 2).
Key Strengths:
Passed Filters: ✓ Yes Notes: Passed all screening filters
Composite Score: 2.80/5.0 Percentile Rank: 50%
Factor Scores:
Setup Score: 6/8 Setup Notes: Strong uptrend (above both SMAs); High volume today (2.1x); Strong weekly momentum; Chart patterns: Recent Breakout
Price Levels:
Momentum & Volume:
Chart Patterns:
Technical Risk Factors:
Risk Level: EXTREME Confidence: 30.0/100 Total Red Flags: 2 Earnings Risk: No
Critical Issues:
Market Red Flags:
This report is generated by PM automated research system. Always perform your own due diligence before trading.